The company logo is located on March 17, 2024 outside the Eli Lilly headquarters in Indianapolis, Indiana.
Scott Olson | Getty Images
Yililai Wednesday said due to the right demand Its massive weight loss and diabetes injection Soars and the company develop new drugs for other diseases.
It is a work with pharmaceutical manufacturers and companies in different industries Establish goodwill With the President Donald Trumphe stressed that manufacturing is relocated to the United States and reduce reliance on foreign supply chains. Eli Lilly made the announcement at an event in Washington, D.C., highlighting the political qualities of the strategy.
This move brings Elli Lilly’s overall Manufacturing Investment In recent years, it has exceeded US$50 billion. The other $23 billion comes from the company New factory and on-site expansion Since 2020 Easy supply shortage Its popular medicine.
Three future U.S. websites announced Wednesday that they will produce the active ingredients of drugs such as Tilzapeptide, which is the active ingredient of Eli Lilly’s obesity drug drug and the treatment of diabetes.
According to the press release, the fourth site will expand the company’s global manufacturing network for future injection therapy.
The new investment is not just dedicated to Eli Lilly’s current and future obesity and diabetes treatments. The company is drawing its future for the future beyond Zepbough and Mounjaro Cancer, Alzheimer’s disease and other conditions.
“Lily’s optimism about the potential of pipelines across the therapeutic field – cardiac metabolic health, oncology, immunology and neuroscience – drives our efforts toward our domestic manufacturing industry,” Eli Lilly Ceo David Ricks said in a statement Wednesday. An unprecedented commitment.”
Nevertheless, the new investment is based on the success of Zepbough and Mounjaro Novo NordiskWeight loss medications and diabetes treatment Ozempic. Some analysts expect the global obesity drug market to be worth it More than $150 billion per year By the early 2030s, both companies must maintain their share as other drugmakers scramble for the first time.
Ricks added that the announcement “reflects our commitment to exceed the expected demand for safety, quality, (FDA) in the future.”
Eli Lilly’s efforts to enhance Zepbough and Mounjaro supply are designed to ensure qualified patients safely access these branded treatments, rather than cheaper composite versions. When branded drugs are inadequate, or if they do not have expensive treatment insurance, patients flock to unapproved imitators.
Since then, the FDA has Announce The shortage of Tirzepatide will essentially ban many compound pharmacy production imitations.
Eli Lilly said the four new locations will create more than 3,000 jobs for workers such as engineers and scientists, and create 10,000 construction jobs when building the factory. The company’s other U.S. factories include the websites of North Carolina, Indiana and Wisconsin.
Ricks touted Trump Tax Cuts and Employment Act 2017said the legislation has become the “basis” of companies’ manufacturing investment. He said these policies are crucial to extend this year. ”
Key provisions of the law will expire at the end of December – although the reduction in corporate tax rates will remain in effect.
In Trump’s first term, the legislation passed by most public conventions is The biggest overhaul of tax law In nearly three decades, taxes for individuals and businesses have been cut. It lowered the corporate tax rate to 21%, reduced the deductions of state and local taxes to $10,000, and expanded the child tax credit, among other things.
Novo Nordisk similarly invested in billions of dollars in manufacturing to increase supply to Wegovy and Ozempic, and announced in 2024 that it would take over three locations at contract maker Catealent for $11 billion.
